Treatment Strategies and Survival Outcomes in Breast Cancer
Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and t...
Saved in:
| : | |
|---|---|
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (264 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04207nam-a2201261z--4500 | ||
|---|---|---|---|
| 001 | 993548397804498 | ||
| 005 | 20231214133259.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202102s2020 xx |||||o ||| 0|eng d | ||
| 020 | |a 3-03928-759-1 | ||
| 035 | |a (CKB)4100000011302294 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/61309 | ||
| 035 | |a (EXLCZ)994100000011302294 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Cheung, Kwok-Leung |4 auth | |
| 245 | 1 | 0 | |a Treatment Strategies and Survival Outcomes in Breast Cancer |
| 260 | |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (264 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival. | ||
| 546 | |a English | ||
| 653 | |a relative survival | ||
| 653 | |a young women | ||
| 653 | |a cancer treatment | ||
| 653 | |a fulvestrant | ||
| 653 | |a lapatinib | ||
| 653 | |a tumor biology | ||
| 653 | |a antihormone therapy | ||
| 653 | |a mastectomy | ||
| 653 | |a aromatase inhibitors | ||
| 653 | |a chemotherapy | ||
| 653 | |a serum biomarker | ||
| 653 | |a cyclin E | ||
| 653 | |a anthracycline resistance | ||
| 653 | |a zero-inflated Poisson regression model | ||
| 653 | |a lymph-node ratio | ||
| 653 | |a CHEK2 | ||
| 653 | |a comparative effectiveness | ||
| 653 | |a breast-conserving therapy | ||
| 653 | |a taxane sensitivity | ||
| 653 | |a liquid biopsy | ||
| 653 | |a HER2 c-erbB2 | ||
| 653 | |a colorectal cancer | ||
| 653 | |a infiltrating breast cancer | ||
| 653 | |a survival | ||
| 653 | |a exercise characteristics | ||
| 653 | |a lactate dehydrogenase | ||
| 653 | |a biomarker | ||
| 653 | |a breast cancer survivors | ||
| 653 | |a BRCA | ||
| 653 | |a disease-free survival | ||
| 653 | |a PIK3CA | ||
| 653 | |a metastatic breast cancer | ||
| 653 | |a cell-free DNA | ||
| 653 | |a invasive breast cancer | ||
| 653 | |a radiotherapy | ||
| 653 | |a Metformin | ||
| 653 | |a social well-being | ||
| 653 | |a gene expression | ||
| 653 | |a contralateral breast cancer | ||
| 653 | |a basal-like breast cancer | ||
| 653 | |a LMK-235 | ||
| 653 | |a Src kinase | ||
| 653 | |a HER2/neu | ||
| 653 | |a LKB1 | ||
| 653 | |a Older women | ||
| 653 | |a LDH | ||
| 653 | |a mutation carriers | ||
| 653 | |a stage IV | ||
| 653 | |a mammography screening | ||
| 653 | |a NCDB | ||
| 653 | |a cMet | ||
| 653 | |a SEER | ||
| 653 | |a pertuzumab | ||
| 653 | |a physical function | ||
| 653 | |a outcome | ||
| 653 | |a ribociclib | ||
| 653 | |a older patients | ||
| 653 | |a geriatric oncology | ||
| 653 | |a metastatic | ||
| 653 | |a overdiagnosis | ||
| 653 | |a next-generation sequencing | ||
| 653 | |a abemaciclib | ||
| 653 | |a Endocrine therapy | ||
| 653 | |a monitoring metastatic breast cancer | ||
| 653 | |a breast cancer | ||
| 653 | |a circulating tumor cells | ||
| 653 | |a Breast Cancer | ||
| 653 | |a PALB2 | ||
| 653 | |a histone deacetylase | ||
| 653 | |a prognosis | ||
| 653 | |a physical activity | ||
| 653 | |a trastuzumab | ||
| 653 | |a ductal carcinoma in situ | ||
| 653 | |a contralateral prophylactic mastectomy | ||
| 653 | |a ERCC1 | ||
| 653 | |a family history | ||
| 653 | |a T-DM1 | ||
| 653 | |a ATM | ||
| 653 | |a advanced breast cancer | ||
| 653 | |a incidence | ||
| 653 | |a palbociclib | ||
| 653 | |a HDAC5 inhibitors | ||
| 653 | |a APOBEC3B | ||
| 776 | |z 3-03928-758-3 | ||
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:49:05 Europe/Vienna |f system |c marc21 |a 2020-06-20 22:16:43 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338781930004498&Force_direct=true |Z 5338781930004498 |b Available |8 5338781930004498 | ||